Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Some patients reluctantly shifted to save money while others have appealed for coverage of Zepbound after having experienced ...

Paul Curran, MPharm, a clinical pharmacist with Optimal You in the UK, says there is one nasty side effect, in particular, ...

A new study suggests that drugs like Ozempic and Mounjaro may reduce dementia risk. Researchers at the University of Galway found a 45% lower risk in ...

India's weight-loss game is getting serious! The country's anti-obesity market is now worth ₹628 crore, and it's climbing ...

A little weight gain during the menopause is normal, but when it happens to a generation who came of age in the skinny-chic ...

Ozempic and Mounjaro are both very popular for weight loss at the minute, but there's one big difference between the two ...

Weight loss jabs such as Wegovy and Mounjaro may offer a protective effect against dementia and stroke, according to a new ...